Psoriasis/Psoriatic Arthritis Patients' Long-term Treatment Patterns and Adherence to Systemic Treatments Monitoring Recommendations

被引:4
|
作者
Krantz, Asa [1 ,2 ]
Carrero, Juan Jesus [3 ,4 ]
Yang, Yuanhang [3 ]
Schalin, Lovisa [5 ]
Lysell, Josefin [1 ,2 ]
Mazhar, Faizan [3 ,6 ]
机构
[1] Karolinska Univ Hosp, Danderyd Hosp, Unit Dermatol, Stockholm, Sweden
[2] Danderyd Hosp, Karolinska Inst, Dept Med Solna, Dermatol & Venereol Sect, Stockholm, Sweden
[3] Danderyd Hosp, Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[4] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Div Nephrol, Stockholm, Sweden
[5] Amgen Inc, Solnam, Sweden
[6] Karolinska Inst, Dept Med Epidemiol & Biostat MEB, Nobels Vag 12A,Box 281, Stockholm, SE, Brazil
基金
瑞典研究理事会;
关键词
adherence; persistence; treatment patterns; guide; PSORIATIC-ARTHRITIS; BIOLOGICS; THERAPIES; TRENDS;
D O I
10.2340/actadv.v103.6505
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Limited information exists regarding treatment of patients with psoriasis/psoriatic arthritis in primary care. The aim of this study is to assess treatment patterns, adherence, persistence, and compliance in newly diagnosed patients with psoriasis/psoriatic arthritis from 2012 to 2018 in Stockholm, Sweden. In addition, laboratory monitoring before initiation of treatment and at recommended intervals was quantified for patients prescribed methotrexate or biologics. A total of 51,639 individuals were included, with 39% initiating treatment with topical corticosteroids and < 5% receiving systemic treatment within 6 months post-diagnosis. During a median (interquartile range) follow-up of 7 (4-8) years, 18% of patients received systemic treatments at some point. Overall, 5-year persistence rates were 32%, 45% and 19% for methotrexate, biologics, and other systemic treatments, respectively. Pre-initiation laboratory tests, as recommended by guidelines, were performed in approximately 70% and 62% of methotrexate and biologics users, respectively. Follow-up monitoring at recommended time intervals occurred in 14-20% and 31-33% of patients prescribed methotrexate and biologics, respectively. These findings highlight gaps in the pharmacological care of patients with psoriasis/ psoriatic arthritis, including suboptimal adherence/ persistence and inadequate laboratory monitoring.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
    Philip J. Mease
    April W. Armstrong
    Drugs, 2014, 74 : 423 - 441
  • [22] Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis
    Feldman, Steven R.
    Pelletier, Corey L.
    Wilson, Kathleen L.
    Mehta, Rina K.
    Brouillette, Matthew A.
    Smith, David
    Bonafede, Machaon M.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (09) : 699 - 708
  • [23] Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics
    Asahina, Akihiko
    Umezawa, Yoshinori
    Yanaba, Koichi
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2016, 43 (07) : 779 - 784
  • [24] Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
    Jashin J. Wu
    Corey Pelletier
    Brian Ung
    Marc Tian
    Ibrahim Khilfeh
    Jeffrey R. Curtis
    Advances in Therapy, 2020, 37 : 2098 - 2115
  • [25] Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
    Chastek, Benjamin
    Fox, Kathleen M.
    Watson, Crystal
    Gandra, Shravanthi R.
    ADVANCES IN THERAPY, 2012, 29 (08) : 691 - 697
  • [26] Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    Khilfeh, Ibrahim
    Curtis, Jeffrey R.
    ADVANCES IN THERAPY, 2020, 37 (05) : 2098 - 2115
  • [27] Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
    Benjamin Chastek
    Kathleen M. Fox
    Crystal Watson
    Shravanthi R. Gandra
    Advances in Therapy, 2012, 29 : 691 - 697
  • [28] Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015
    Lee, Moa P.
    Lii, Joyce
    Jin, Yinzhu
    Desai, Rishi J.
    Solomon, Daniel H.
    Merola, Joseph F.
    Kim, Seoyoung C.
    ARTHRITIS CARE & RESEARCH, 2018, 70 (05) : 791 - 796
  • [29] Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus
    Hsu, Chung-Yuan
    Lin, Yu-Sheng
    Cheng, Tien-Tsai
    Syu, Ya-Jhu
    Lin, Ming-Shyan
    Lin, Hsing-Fen
    Su, Yu-Jih
    Chen, Ying-Chou
    Chen, Jia-Feng
    Chen, Tien-Hsing
    RHEUMATOLOGY, 2018, 57 (10) : 1743 - 1751
  • [30] A Case Report of Psoriatic Arthritis with Long-Term Use of NSAID
    Manoj Dikkatwar
    Ritika Bhagat
    Radhika Bindu
    Mrudangsinh Rathod
    Sharad Chand
    Jitendra Vaghasiya
    SN Comprehensive Clinical Medicine, 5 (1)